Partway through an IVF stimulation cycle, many people are told to add a second daily shot: ganirelix (sold as generic ganirelix and as Fyremadel) or Cetrotide (cetrorelix). Its job is simple to state. It keeps your body from releasing eggs on its own before the clinic can retrieve them. Knowing that purpose, and the few reactions worth reporting, makes the extra injection easier to understand and helps you notice the problems that need a same-day call.
Peptides that hold back an early surge
Both drugs are synthetic peptides. The ganirelix label describes it as a synthetic decapeptide, a chain of ten amino acids, with strong blocking activity against naturally occurring gonadotropin-releasing hormone (GnRH), and the Cetrotide label describes cetrorelix the same way. GnRH tells the pituitary gland to release luteinizing hormone (LH). A natural LH surge triggers ovulation, so during stimulation an unplanned surge could release eggs before retrieval. By sitting on the GnRH receptor, these antagonists cause a rapid, reversible drop in LH, and the ganirelix label notes that, unlike agonist drugs such as Lupron, no initial burst of hormone release was detected. Both labels list the same use: inhibiting premature LH surges during controlled ovarian stimulation.
Common reactions and the ones to report
- Skin reactions where you inject. The Cetrotide label says redness, bruising, itching and swelling at the site were usually mild, short and temporary. Tell your clinic if a reaction keeps spreading or does not fade.
- Allergic reactions. Both labels report rare hypersensitivity reactions after marketing, including anaphylaxis, and the Cetrotide label notes reactions with the first dose. Hives, swelling of the face or throat, wheezing or faintness after a shot need emergency care.
- Latex. The ganirelix label lists allergy to dry natural rubber latex, which may be in the rigid needle shield, as a reason not to use it; some packages are made without latex. If you have a latex allergy, tell the clinic and pharmacist and check the package you receive.
- Pregnancy. Known or suspected pregnancy is a contraindication, so clinics confirm you are not pregnant before starting.
Watching for ovarian hyperstimulation
Ovarian hyperstimulation syndrome (OHSS) comes mainly from the stimulation drugs, not from the antagonist, but it is the complication to watch during these weeks. In the ganirelix trials, where every patient was also taking stimulation hormones, OHSS was reported in 2.4%. MedlinePlus says most cases are mild, with bloating, mild belly pain and weight gain, and advises contacting your provider for less urine, dizziness, weight gain of more than 2 pounds a day, nausea so bad you cannot keep food or liquids down, severe belly pain or shortness of breath.
Antagonist protocols are often chosen partly for this reason. A 2023 meta-analysis in Expert Reviews in Molecular Medicine pooled 52 studies with about 10,000 participants and found live birth rates comparable to the long agonist protocol, with evidence of less OHSS, especially in women with polycystic ovary syndrome. It was funded by Chinese government research programs, the authors reported no competing interests, and they noted that earlier reviews disagreed and that cumulative results for some groups, such as poor responders, still need study. Which protocol fits you is a decision for your fertility team.
Practical steps: keep the clinic’s after-hours number handy, write down when each shot is given, and do not skip, add or reschedule injections without asking, because the timing of these drugs is matched to your monitoring scans and blood tests.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the linked sources (fetched 2026-10-07 PT). Not medical advice.
Sources
- DailyMed: Ganirelix acetate injection, label, Organon
- DailyMed: Cetrotide (cetrorelix acetate for injection), label, EMD Serono
- MedlinePlus: Ovarian hyperstimulation syndrome
- Liu C, Tian T, Lou Y, et al. Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF/ICSI: a systematic review and meta-analysis. Expert Reviews in Molecular Medicine, 2023 (PMC full text).